This is the second webinar in the BioMedical SIG webinar series, “From Research to Development – Paths to Cross the Valley of Death in Life Sciences”, which showcases initiatives available to European KTOs to maturate technologies with potential in TRL and CRL, without the creation of a spin-off.
In this session, speakers Peter Nussbaumer and Gernot Faustmann will present the KHAN/w4i/LDC initiative. This collaborative drug discovery platform facilitates the translation of world-class science into innovative therapies for the benefit of patients. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. They focus on first-in-class therapies for attractive markets with a high unmet medical need.
This webinar is organised by the BioMedical SIG and supported by UCB. Join the BioMedical SIG to stay informed.
The software course has provided invaluable information as our TTO expands to take on software cases.
Tom Withnell
University of Vienna, Austria
Recent studies on both sides of the Atlantic, directed by either ASTP or AUTM, demonstrate the tremendous economic and societal benefit and value technology transfer has brought us.
Koenraad Debackere
KU Leuven, Belgium
This course offers an opportunity to meet likeminded people, share tips and tricks, and dive into different approaches to help you set up and improve KTO processes.
Brechtje Vreenegoor
Radboud University, Netherlands
Good opportunity to discuss common issues with fellow professionals and to get updates about the community.
Giuseppe Visimberga
Leiden University, Netherlands
ASTP brought the right structure and terminology to my knowledge of technology licensing.
René Widmer
ETH Transfer, Switzerland
Join our newsletter and get the latest news